Genetic Polymorphism of XRCC1 Correlated with Resp

Authors: Hongying Lv Qicai Li Wengsheng Qiu Jinyu Xiang Hongjun Wei Hua Liang Aihua Sui Jun Liang

Publish Date: 2012/05/02

Volume: 18, Issue: 4, Pages: 1009-1014

PDF Link

Abstract

To examine the association between genetic polymorphisms of XRCC1 Arg399GlnG→A and response to oxaliplatinbased chemotherapy in advanced colorectal cancer XRCC1 genotypes of totally 99 patients37 stage III 62 stage IVwith advanced colorectal cancer treated with oxaliplatinbased chemotherapy were detected by TaqManMGB probe allelic discrimination method And clinical response of 62 patients in stage IVafter 2 to 3 cycles of chemotherapy were evaluated Also time to progress TTP of all patients were evaluated Of the genotype frequencies in all patients up to 5253  were G/G genotype 909  were A/A genotype and 3838  were G/A genotype The response rate CR+PR of 62 patients in stage IV was 6129  19/31 Patients with G/G genotype showed enhanced respond to chemotherapy compared to those with G/A+A/A x 2 = 56 P = 0029 OR = 3845 95 CI = 1231 ~ 1201 P = 0018 Individuals with the G/G genotype had a TTP of 100 888–1112 months those with the G/A+A/A genotype had an TTP of 50426–574 months The logrank test was marginally significant x 2 = 2920 P  001 The Cox proportional hazards model adjusted for stage performance status and chemotherapy regimen showed that only XRCC1 G/G genotypes increases the OR significantly OR = 3555 95  CI 2119 ~ 5963 P  001 The results suggest that XRCC1 Arg399Gln polymorphisms is associated with the response to oxaliplantinbased chemotherapy and time to progression in advanced colorectal cancer in Chinese population It is proposed that the XRCC1 Arg399Gln polymorphism should be routinely detected to screen patients who are more likely benefit from oxaliplantinbased treatment

Keywords: